UC Davis/NIH NeuroMab Facility-Administrative Supplement

 描述(由申请人提供)：高质量、可靠和单特异性的小鼠单抗(MAbs)的可用性已经被验证和优化用于哺乳动物的大脑(即NeuroMabs)，对神经科学研究的许多领域至关重要。对大脑中表达的每一种蛋白质都有这样的试剂是必要的，以便进行生化和免疫组织化学研究，开始将基于基因组的方法获得的核酸序列信息与大脑中编码基因产物的功能联系起来。不幸的是，缺乏针对特定基因产物的抗体，或缺乏特异性的抗体，可能会严重阻碍神经科学研究的整个子领域，从而阻碍理解神经疾病基础机制的进展。加州大学戴维斯分校/美国国立卫生研究院NeuroMab基金通过两种主要方式来满足这一未得到满足的需求：通过为NIH认为高度优先的目标生成神经单抗，并以低成本的非营利性基础将它们分发给神经科学研究社区。来自加州大学戴维斯分校和美国国立卫生研究院各种来源的种子资金使我们在2005年创建了我们的设施，在过去的九年里，我们承担了针对400多种大脑蛋白质的mAb项目，并生成了一份超过370种神经单抗的目录。通过我们的承包商抗体公司(AI)，我们已经以低成本向世界各地许多不同机构的数百名研究人员分发了超过44,500瓶NeuroMabs，我们的最终用户在1500多种原始研究出版物中引用了NeuroMabs的使用。假设保守的营利性价格为每100微克纯化单抗350美元，估计NeuroMab非营利组织为最终用户及其资助机构节省的资金超过1250万美元。我们已经证明了自己是一家在重要贡献方面有着良好记录的机构，我们希望继续尽我们所能为神经科学研究人员提供服务。多年来，我们的设施对NIH及其使命的价值已经通过各种资助计划一次又一次地得到证明，最近一次是来自NIH主任的变革性R01计划。此外，NIH、加州大学董事会和人工智能的共同支持和合作使我们自2011年以来能够从分发NeuroMab中获得计划收入，以支持未来设施的自给自足和新的mAb研发。然而，变革性的R01资金和累积的计划收入的组合不足以留住我们经验丰富的高级员工，保持设施以其目前的生产力水平运行，并继续开展NINDS的高度优先项目。通过额外的R24资金保持来自NIH的强大支持将有助于保留我们宝贵的人力和技术资源，保留我们目前的UC Davis基础设施，并保持我们的特殊保护，使其免受版税和许可附加费的影响，这些费用将不必要地提高我们最终用户的NeuroMabs价格。

 DESCRIPTION (provided by applicant): The availability of high-quality, reliable and monospecific mouse monoclonal antibodies (mAbs) that have been validated and optimized for use in mammalian brain (i.e. NeuroMabs) is of utmost importance to many areas of neuroscience research. Having such reagents for each of the proteins expressed in the brain is necessary to undertake biochemical and immunohistochemical studies to begin to link the nucleic acid sequence information derived from genome-based approaches to the function of the encoded gene products in the brain. Unfortunately, the lack of antibodies against a particular gene product, or antibodies that lack specificity, can severely handicap an entire subfield of neuroscience research and thereby impede progress towards understanding the mechanisms that underlie neurological disease. The UC Davis/NIH NeuroMab Facility works towards this unmet need in two major ways: by generating NeuroMabs for targets that are deemed high-priority by NIH and by distributing them on a low-cost non-profit basis to the neuroscience research community. Seed funds from UC Davis and various NIH sources allowed for the creation of our Facility in 2005 and, over the past nine years, we have undertaken mAb projects against over 400 brain proteins and generated a catalog of over 370 NeuroMabs. Through our contractor Antibodies Incorporated (AI), we have distributed over 44,500 vials of NeuroMabs at low cost to hundreds of researchers at a multitude of different institutions worldwide and our end users have cited the use of NeuroMabs in over 1500 original research publications. Assuming a conservative for-profit price of $350 per 100 µg vial of purified mAb, an estimate of the NeuroMab non-profit savings to end users and their respective funding agencies is over $12.5 million. We have proven ourselves to be an establishment with a strong track record of important contributions and we wish to continue serving neuroscience researchers as best as we can. The worthiness of our Facility to the NIH and its mission has been demonstrated time and again through various funding initiatives over the years, most recently from the NIH Director's Transformative R01 Program. In addition, the combined support and cooperation of the NIH, the Regents of the University of California and AI have enabled us since 2011 to collect program income from the distribution of NeuroMabs to support future Facility self-sufficiency and new mAb research and development. However, the combination of the Transformative R01 funds and the accumulated program income is insufficient to hold onto our experienced senior staff, to keep the Facility running at its present-day level of productivity and to continue doing projects of high priority to NINDS. Maintaining strong support from NIH through additional R24 funding would be instrumental to retaining our valuable human and technological resources, preserving our current UC Davis infrastructure and keeping intact our exceptional protection from royalty and licensing surcharges that would unnecessarily raise the prices of NeuroMabs for our end users.